Induction of resistance to azole drugs in Trypanosoma cruzi

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 12, 1998, Pages 3245-3250

  Buckner, Frederick S ^a   Wilson, Aaron J ^a   White, Theodore C ^a,b   Van Voorhis, Wesley C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 1 [3 [2 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL]VINYL] 1,2,4 TRIAZOL 1 YL] 3 (1,2,4 TRIAZOL 1 YL) 2 PROPANOL; AMPHOTERICIN B; ANTIPROTOZOAL AGENT; BENZNIDAZOLE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN 3T3; CHAGAS DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PARASITE CULTIVATION; PRIORITY JOURNAL; TRYPANOSOMA CRUZI;

EID: 0031761201     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.12.3245     Document Type: Article

References (47)

1. Ajioka, J., and J. Swindle. 1996. The calmodulin-ubiquitin (CUB) genes of Trypanosoma cruzi are essential for parasite viability. Mol. Biochem. Parasitol. 78:217-225.
2. Albertson, G. D., M. Niimi, R. D. Cannon, and H. F. Jenkinson. 1996. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob. Agents Chemother. 40:2835-2841.
3. Apt, W., X. Aguilera, A. Arribada, C. Perez, C. Miranda, G. Sanchez, I. Zulantay, P. Cortes, J. Rodriguez, and D. Juri. 1998. Treatment of chronic Chagas' disease with itraconazole and allopurinol. Am. J. Trop. Med. Hyg. 59:133-138.
4. Bacchi, C. J. 1993. Resistance to clinical drugs in African trypanosomes. Parasitol. Today 9:190-193.
5. Beverley, S. M. 1991. Gene amplification in Leishmania. Annu. Rev. Microbiol. 45:417-444.
6. Borst, P., and M. Ouellette. 1995. New mechanisms of drug resistance in parasitic protozoa. Annu. Rev. Microbiol. 49:427-460.
7. Brener, Z. 1993. An experimental and clinical assay with ketoconazole in the treatment of Chagas disease. Mem. Inst. Oswaldo Cruz 88:149-153.
8. Buckner, F. S., C. L. M. J. Verlinde, A. C. La Flamme, and W. C. Van Voorhis. 1996. Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing β-galactosidase. Antimicrob. Agents Chemother. 40:2592-2597.
9. Buckner, F. S., B. T. Wipke, and W. C. Van Voorhis. 1997. Trypanosoma cruzi infection does not impair major histocompatibility complex class I presentation of antigen to cytotoxic T lymphocytes. Eur. J. Immunol. 27:2541-2548.
10. Calvet, H. M., M. R. Yeaman, and S. G. Filler. 1997. Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob. Agents Chemother. 41:535-539.
11. Croft, S. L. 1997. The current status of antiparasitic chemotherapy. Parasitology 114:S3-S15.
12. 2 gene in Trypanosoma cruzi. Mol. Biochem. Parasitol. 75:145-147.
13. Docampo, R. 1981. Biochemical and ultrastructural alterations produced by miconazole and econazole in Trypanosoma cruzi. Mol. Biochem. Parasitol. 3:169-180.
14. Docampo, R., and G. A. Schmunis. 1997. Sterol biosynthesis inhibitors: potential chemotherapeutics against Chagas disease. Parasitol. Today 13: 129-130.
15. Filardi, L. S., and Z. Brener. 1987. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas' disease. Trans. R. Soc. Trop. Med. Hyg. 81:755-759.
16. Foote, S. J., and A. F. Cowman. 1994. The mode of action and the mechanisms of resistance to antimalarial drugs. Acta Trop. 56:157-171.
17. Goad, L. J., R. L. Berens, J. J. Marr, D. H. Beach, and G. G. Holz. 1989. The activity of ketoconazole and other azoles against Trypanosoma cruzi: biochemistry and chemotherapeutic action in vitro. Mol. Biochem. Parasitol. 32:179-190.
18. Guieros-Filho, F., A. P. B. Viola, F. C. A. Gomes, M. Farina, U. Lins, A. L. Bertho, D. F. Wirth, and U. G. Lopes. 1995. Leishmania amazonensis: multidrug resistance in vinblastine-resistant promastigotes is associated with rhodamine 123 efflux, DNA amplification, and RNA overexpression of a Leishmania mdr 1 gene. Exp. Parasitol. 81:480-490.
19. Johnson, P. J. 1993. Metronidazole and drug resistance. Parasitol. Today 9:183-186.
20. Joseph-Home, T., and D. W. Hollomon. 1997. Molecular mechanisms of azole resistance in fungi. FEMS Microbiol. Lett. 149:173-180.
21. Kirchhoff, L. V. 1993. American trypanosomiasis (Chagas disease) - a tropical disease now in the United States. N. Engl. J. Med. 329:639-644.
22. La Flamme, A. C., F. S. Buckner, J. Swindle, J. Ajioka, and W. C. Van Voorhis 1996 Trypanosoma cruzi: expression of interleukin-2 utilizing both supercoiled plasmids and linear DNA. Exp. Parasitol. 83:159-163.
23. Law, D., C. B. Moore, H. M. Wardle, L. A. Ganguli, M. G. Keaney, and D. W. Denning. 1994. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J. Antimicrob. Chemother. 34:659-668.
24. Lazardi, K., J. A. Urbina, and W. de Souza. 1990. Ultrastructural alterations induced by two ergosterol biosynthesis inhibitors, ketoconazole and terbinafine, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother. 34:2097-2105.
25. Maldonado, R. A., J. Molina, G. Payares, and J. A. Urbina. 1993. Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas' disease. Antimicrob. Agents Chemother. 37: 1353-1359.
26. McCabe, R. E., J. S. Remington, and F. G. Araujo. 1987. Ketoconazole promotes parasitological cure of mice infected with Trypanosoma cruzi. Trans. R. Soc. Trop. Med. Hyg. 81:613-615.
27. McCabe, R. E., J. S. Remmington, and F. G. Araujo. 1986. In vitro and in vivo effects of itraconazole against Trypanosoma cruzi. Am. J. Trop. Med. Hyg. 35:280-284.
28. Medical Economics Data Production Co. 1997. Physicians Desk Reference. Medical Economics Data Production Co, Montvale, N.J.
29. Molina, J. T., M. S. S. Araujo, M. E. S. Pereira, Z. Brener, and J. A. Urbina. 1997. Activity of the bis-triazole D0870 against drug-resistant Trypanosoma cruzi strains, abstr. B-416, p. 34. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
30. Moreira, A. A., H. B. de Souza, V. Amato-Neto, L. Matsubara, P. L. Pinto, J. E. Tolezano, E. V. Nunes, and M. Okumura. 1992. Evaluation of the therapeutic activity of itraconazole in chronic infections, experimental and human, by Trypanosoma cruzi. Rev. Inst. Med. Trop. Sao Paulo 34:177-180.
31. Nozaki, T., and J. A. Dvorak. 1993. Molecular biology studies of tubercidin resistance in Trypanosoma cruzi. Parasitol. Res. 79:451-455.
32. Ouellette, M., F. Fase-Fowler, and P. Borst. 1990. The amplified H circle of methotrexate-resistant Leishmania tarentolae contains a novel P-glycoprotein gene. EMBO J. 9:1027-1033.
33. Ouellette, M., and B. Papadopoulou. 1993. Mechanisms of drug resistance in Leishmania. Parasitol. Today 9:150-153.
34. Polak, A., and R. Richle. 1978. Mode of action of the 2-nitroimidazole derivative benznidazole. Ann. Trop. Med. Parasitol. 72:45-54.
35. Ruhnke, M., A. Eigler, E. Engelmann, B. Geiseler, and M. Trautmann. 1994. Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatment with fluconazole. Infection 22:132-136.
36. Sanglard, D., K. Kuchler, J. L. Pagani, M. Nonod, and J. Bille. 1995. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39:2378-2386.
37. Schapira, A., P. F. Beales, and M. E. Halloran. 1993. Malaria: living with drug resistance. Parasitol. Today 9:168-174.
38. Solari, A., H. Saavedra, C. Sep'ulveda, D. Odd'o, G. Acuna, J. Labarca, S. Munoz, G. Cuny, C. Grengues, and F. Veas. 1993. Successful treatment of Trypanosoma cruzi encephalitis in a patient with hemophilia and AIDS. Clin. Infect. Dis. 16:255-259.
39. Ullman, B. 1995. Multidrug resistance and P-glycoproteins in parasitic protozoa. J. Bioenerg. Biomembr. 27:77-84.
40. Upcroft, J. A., and P. Upcroft. 1993. Drug resistance and Giardia. Parasitol. Today 9:187-190.
41. Urbina, J. A. 1997. Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitology 114:S91-S99.
42. Urbina, J. A., K. Lazardi, T. Aguirre, M. M. Piras, and R. Piras. 1988. Antiproliferative synergism of the allylamine SF 86-327 and ketoconazole on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother. 32:1237-1242.
43. Urbina, J. A., B. Payares, J. Molina, C. Sanoja, A. Liendo, K. Lazardi, M. M. Piras, R. Piras, P. Wincker, and J. F. Ryley. 1996. Cure of short- and long-term experimental Chagas' disease using D0870. Science 273:969-971.
44. Urbina, J. A., J. Vivas, H. Ramos, G. Larralde, Z. Aguilar, and L. Avilan. 1988. Alteration of lipid order profile and permeability of plasma membranes from Trypanosoma cruzi epimastigotes grown in the presence of ketoconazole. Mol. Biochem. Parasitol. 30:185-196.
45. Van Voorhis, W. C., and H. Eisen. 1989. FL-160: a surface antigen of Trypanosoma cruzi that mimics mammalian nervous tissue. J. Exp. Med. 169:641-652.
46. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
47. World Health Organization. 1991. Control of Chagas' disease, p. 1-93. WHO Technical Report Series no. 811. World Health Organization. Geneva, Switzerland.